anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was \<12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enhancing anti-tumour immune responses, demonstrating significant efficacy in various malignancies, including melanoma. However, over 50% of patients experience limited or no response to ICI therapy. Resistance to ICIs is influenced by a complex interplay of tumour intrinsic and extrinsic factors. This review summarizes current ICIs for melanoma and the factors involved in resistance to the treatment. We also discuss emerging evidence that the microbiota can impact ICI treatment outcomes by modulating tumour biology and anti-tumour immune function. Furthermore, microbiota profiles may offer a non-invasive method for predicting ICI response. Therefore, future research into microbiota manipulation could provide cost-effective strategies to enhance ICI efficacy and improve outcomes for melanoma patients.
The invention relates to a salbutamol sulfate film-controlled slow-release pellet capsule. A slow-release film of the salbutamol sulfate film-controlled slow-release pellet utilizes Kollicoat SR30D as a film-formation material. A pellet core of the salbutamol sulfate film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 5 to 20wt% of the sodium carboxymethyl starch. The slow-release film comprises Kollicoat SR30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR30D to triethyl citrate to talcum powder is 30: 1: 4 and a film weight increasing ratio is in a range of 19 to 38%. The salbutamol sulfate film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the salbutamol sulfate film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the salbutamol sulfate film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
Pharmacogenetics was used to evaluate the effect of polymorphisms in select candidate genes on the response of patients with chronic constipation to tegaserod (Zelmac®/Zelnorm®). The analysis identified twelve single nucleotide polymorphisms (SNPs) in six genes (HTR4, HTR3B, MLN, AQP3, SLC12A2, SCNN1A) that were associated with at least a 60% response rate to tegaserod and an odds ratios of 5 or greater (compared to placebo) after 4 weeks of treatment. The identified genes display a wide range of different functions, including serotonin signaling, secretion and motility, all of which are important in maintaining the normal function of the gastrointestinal tract. Thus, these data imply that chronic constipation may result from a variety of pathophysiological mechanisms related to variants in the above identified genes, all of which respond well to treatment with tegaserod. Patients without these variants do not respond to treatment significantly more than they do to placebo, which could indicate that their chronic constipation is not due to pathophysiological mechanisms but rather to environmental or possibly psychological factors. Patients with these variants are also less likely to respond to placebo, again implying that these variants are associated with a true pathophysiology.
The invention provides a fusion protein, a porcine epidemic diarrhea vaccine composition containing the fusion protein and application thereof. The fusion protein contains porcine epidemic diarrhea virus antigenic protein and immunoglobulin Fc segment, wherein the porcine epidemic diarrhea virus antigenic protein contains a protein formed by series combination of porcine epidemic diarrhea virus S protein segments. The invention also provides a porcine epidemic virus vaccine composition which contains the fusion protein and a carrier. The invention also provides a preparation method of the vaccine composition and application of the vaccine composition in preparing drugs for preventing and/or treating diseases initiated by porcine epidemic diarrhea virus. The vaccine composition prepared from the fusion protein avoids the technical problem that the porcine epidemic diarrhea virus totivirus can not be easily separated and cultured in the traditional vaccine inactivation process. The fusion protein can utilize the gene engineering technique to perform abundant recombinant expressions, has the advantage of short time consumption, and is convenient for large-scale production.
Determining the genetic contributions to Parkinson's disease (PD) across diverse ancestries is a high priority as this work can guide therapeutic development in a global setting. The genetics of PD spans the etiological risk spectrum, from rare, highly deleterious variants linked to monogenic forms with Mendelian patterns of inheritance, to common variation involved in sporadic disease. A major limitation in PD genomics research is lack of racial and ethnic diversity. Enrollment disparities have detrimental consequences on the generalizability of results and exacerbate existing inequities in care. The Black and African American Connections to Parkinson's Disease (BLAAC PD) study is part of the Global Parkinson's Genetics Program, supported by the Aligning Science Across Parkinson's initiative. The goal of the study is to investigate the genetic architecture underlying PD risk and progression in the Black and/or African American populations. This cross-sectional multicenter study in the United States has a recruitment target of up to 2,000 individuals with PD and up to 2,000 controls, all of Black and/or African American ancestry. The study design incorporates several strategies to reduce barriers to research participation. The multifaceted recruitment strategy aims to involve individuals with and without PD in various settings, emphasizing community outreach and engagement. The BLAAC PD study is an important first step toward informing understanding of the genetics of PD in a more diverse population.
Common eland bulls are important game ranching animals in southern Africa, for tourism, breeding/live sales, trophy hunting, and game meat production. Interest has grown in their production potential, intensifying animal husbandry and breeding approaches. However, little scientific information is available regarding the intensive management of this species, including information regarding scientifically based selection criteria for breeding bulls. Often, simple phenotypic traits are utilised unless high-value game animals are being bred, with horn and body size often being the only traits considered for breeding bulls. This study provides basic information about the reproductive tract morphology, symmetry, and their relationships with secondary sexual traits, social rank, and temperament in common eland. Six eland males (2-2.5 years old; 203 ± 20 kg) were utilised for the study. Social rank, body weight and body condition score, temperament score, and horn size were determined before the animals were culled, and their reproductive tracts were collected for morphometric and histological evaluation. Results indicate relatively low asymmetry in bilateral reproductive tract components. Individual traits of eland bulls such as age, body weight, and social rank correlated the development of some testicular morphologies and thus may possibly be used in zoos, game ranching, and commercial production for the selection of breeding males, but not temperament and horn length, which should be carefully evaluated. Whilst this study provides baseline information from a limited sample size, further studies should incorporate the assessment of testicular hemodynamics, as well as the effects of factors such as season and androgen secretion patterns over a wider age range of common eland males and populations to provide further information for the management practices of breeding common eland bulls.
PURPOSE:To obtain a soft antitussive and expectorant capsule containing a liquid in which antitussive and expectorant drug action ingredient is dissolved, easily administrative by oral route, unnecessary in troublesome weighting, having excellent portable property and fast acting property. CONSTITUTION:The objective capsule containing a liquid in which at least one kind of antitussive and expectorant drug action ingredient is dissolved. As the drug action ingredient, central antitussive (e.g. thiphepisin citrate), bronchodilator (e.g. dl-methylephedrine hydrochloride) and noscapine, etc., is used. As the liquid, at least one kind of compound selected from at least one kind of antitussive and expectorant drug action ingredients, saccharides (e.g. at least one kind of saccharide selected from sorbit, xylit and maltit), surfactant (e.g. polyoxyethylene hardened castor oil, polyethylene glycol monostearate, etc.) and high polymer compound (e.g. polyvinylpyrrolidone, carboxyvinyl polymer, etc.) and polyethylene glycol solution containing acid (e.g. citric acid, malic acid, tartaric acid, etc.) are used.
BACKGROUND: Minimally invasive direct coronary artery bypass (MIDCAB) surgery offers an effective option for coronary artery disease (CAD) patients with the avoidance of median sternotomy and fast postoperative recovery. However, MIDCAB is still associated with significant postoperative pain which may lead to delayed recovery. The erector spinae plane block (ESPB) is a superficial fascial plane block. There have not been randomized controlled trials evaluating the effects of ESPB on analgesia and patient recovery following MIDCAB surgery. We therefore designed a double-blind prospective randomized placebo-controlled trial, aiming to prove the hypothesis that ESPB reduces postoperative pain scores in patients undergoing MIDCAB surgery.
METHODS: The study protocol has been reviewed and approved by the Ethical Review Committee of Peking University People's Hospital. Sixty adult patients of either sex scheduled for MIDCAB surgery under general anesthesia (GA) will be included. Patients will be randomly allocated to receive either a preoperative single-shot ESPB with 30 mL of ropivacaine 0.5% (ESPB group) or normal saline 0.9% (control group). The primary outcomes are the difference between the two groups in numeric rating scale (NRS) scores at rest at different time points (6, 12, 18, 24, 48 h) after surgery. The secondary outcomes include NRS scores on deep inspiration within 48 h, postoperative hydromorphone consumption, and quality of patient recovery at 24 h and 48 h, using the Quality of Recovery-15 (QoR-15) scale. The other outcomes include intraoperative fentanyl requirements, the need for additional postoperative rescue analgesics, time to tracheal extubation and chest tube removal after surgery, incidence of postoperative nausea and vomiting (PONV) and postoperative cognitive dysfunction (POCD), intensive care unit (ICU) length of stay (LOS), hospital discharge time, and 30-day mortality. Adverse events will be also evaluated.
DISCUSSION: This is a novel randomized controlled study evaluating a preoperative ultrasound-guided single-shot unilateral ESPB on analgesia and quality of patient recovery in MIDCAB surgery. The results of this study will characterize the degree of acute postoperative pain and clinical outcomes following MIDCAB. Our study may help optimizing analgesia regimen selection and improving patient comfort in this specific population.
TRIAL REGISTRATION: The study was prospectively registered with the Chinese Clinical Trial Registry (trial identifier: ChiCTR2100052810). Date of registration: November 5, 2021.
This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
To assure safe and effective use of buspirone hydrochloride tablets, the following information and instructions should be given to patients:

  1. Do not take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.
  2. Do not take an MAOI within 2 weeks of stopping buspirone unless directed to do so by your physician.
  3. Do not start buspirone if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your physician.
  4. Inform your physician about any medications, prescription or non-prescription, alcohol, or drugs that you are now taking or plan to take during your treatment with buspirone hydrochloride tablets.
  5. Inform your physician if you are pregnant, or if you are planning to become pregnant, or if you become pregnant while you are taking buspirone hydrochloride tablets.
  6. Inform your physician if you are breast-feeding an infant.
  7. Until you experience how this medication affects you, do not drive a car or operate potentially dangerous machinery.
  8. You should take buspirone hydrochloride consistently, either always with or always without food.
  9. During your treatment with buspirone hydrochloride tablets, avoid drinking large amounts of grapefruit juice.
Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
PURPOSE: To provide a polyglycerol fatty acid ester mixture, a bathing agent containing the same and an emulsifier, solubilizing agent, dispersant, wetting agent and superfatting agent in compounding to cosmetic, medicinal or chemical industry consisting of this mixture. CONSTITUTION: The polyglycerol fatty acid ester mixture composed of polyglycerol of 2 to 8 in the degree of polymn. and the mono- and di-polyester of at least one kind of satd. and/or unsatd. fatty acids. This mixture is adequate for emulsification and/or solubilization of the etheric oils, mineral oils, animal fats and oils and vegetable fats and oils with which the emulsification and solubilization as they are difficult. Further, this mixture has the nature advantageous in terms of cosmetology and toxicology in addition to its high hydrophilicity. As a result, the mixture lends itself to preparation of cosmetics and medicaments for introduction of the effect of taking caring the skin.
Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain a dental composite restorative material, having optical characteristics essentially close to those of natural teeth and useful for restoring an enamel or formation, etc., of a dental crown comprising the enamel by regulating the light transmittance of a composite restorative material within a specific range. SOLUTION: This dental composite restorative material is regulated so as to provide 0.002-0.3 degree of diffusion D of transmitted light defined by formula I [I is the luminous intensity of light transmitted through a sample; I0 , I20 and I70 are each the luminous intensity (the intensity of light) in the directions at 0, 20 and 70 deg. tilted from the direction vertical to the sample plate (incident directions of light) and the angles of the trigonometric function are same]. When the material is used for restoring an enamel or forming a dental crown comprising the enamel, D is preferably within the range of 0.002-0.01. When the material is used for restoring a dentin or the dental crown or forming the dental crown comprising the dentin, D is preferably within the range of 0.007-0.3.  Furthermore, the material formed into a platy material having 1mm thickness is regulated so as to provide 0.45-0.65 value of the contract ratio C in formula II [Yb is a value of the XYZ color system measured in a black box, etc.; Yw is a value of the XYZ system against a white background (Y=93-97)].
Infections are one of the most serious of ventricular assist device (VAD) related complications. Many of these infections are associated with significant patient morbidity and mortality. Diagnosis of these infections is often difficult due to the complicated nature of the patient's medical problems, the need for rapid institution of empiric antibiotic therapy and the lack of established criteria that define infection. Staphylococci are among the most common causes of VAD infections. The basis for this high incidence is not well understood but is believed to be in part due to inoculation of staphylococcal commensal flora into wound sites at the time of surgery or thereafter. The goals of this observational study are to develop a better understanding of the pathogenesis and epidemiology of Staphylococcus aureus and epidermidis-VAD infections as well as to develop a set of criteria that can be used to help diagnose the presence or absence of a VAD related infection.

This is a prospective, multi-center, observational study to identify risk factors associated with the development of VAD-related infections. Patients will be followed for up to one year following VAD implantation, time of death or transplantation, whichever comes first. There will be no randomization for this observational study.
Within cohort 1 infants will be randomized using a 3:1 scheme to receive sildenafil or placebo. Infants randomized to sildenafil will receive 0.125 mg/kg daily every 8 hours intravenously (IV), or 0.25 mg/kg daily every 8 hours enterally for 28 days.
The present invention relates to a wound dressing structure composition, and more particularly to a composite cell activation and proliferation material composition having antibacterial and antiviral effects. The wound dressing structure composition mainly includes a combination of three-layer structures. The first structure is a base material made of a non-stick base material including but not limited to fibers, yarns and fabrics. The second structure is a nano-gold sputtering layer combined with one side of the base material. The third structure is a blood-sucking cotton fleece combined with the other side of the base material. The use method is to use the nano-gold sputtering layer to face the wound. Since the nano gold has the effects of activating cells and helping blood vessels to proliferate, it can help the wound recovery. Through its non-stick property and the combination of the blood-sucking cotton fleece on the other side, the middle base material can smoothly absorb tissue fluid, avoid the wound from sticking, and facilitate the separation of the dressing from the wound so as to achieve the effect of wound healing.
Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 2 (n=approximately 1435) will receive matching placebo.
<P>PROBLEM TO BE SOLVED: To provide an oral dose composition capable of inhibiting a blood sugar increase, having an effect of preventing diabetes or resisting obesity, having an excellent taste and food value, and capable of being easily ingested, by taking it together with other food and drink at the same time, or before or after the taking thereof, so as to inhibit assimilation of sugar contained in the other food and drink.  <P>SOLUTION: This oral dose composition for inhibiting the postcibal blood sugar increase contains a plant belonging to Brassica oleracea. A juice or an extract of the plant belonging to the Brassica oleracea, a supernatant fraction or a water-insoluble fraction thereof, a powder of the above materials, or another powder of the plant body itself or a dried product of the plant body is used for the composition. Kale (Brassica oleracea L. var. acephala) is preferably used as the plant. The oral composition has the blood sugar increase- inhibiting action and is effectively used as an antidiabetic or obesity-resisting composition.  <P>COPYRIGHT: (C)2004,JPO
The invention provides a healthy product composition or a medical composition containing EGCG and beta-glucan. The medical preparation formulation comprises any medical preparation formulation which can be accepted on pharmaceutics. The EGCG also comprises a derivative thereof. The beta-glucan comprises yeast beta-glucan or oat beta-glucan. The combination manner also comprises that the EGCG and the beta-glucan are respectively made into separate preparations, and the two separate preparations are packaged in the same pill box. The invention further provides the preparation method of the composition, and application of the composition in preparing the drugs for resisting tumors, resisting oxidative stress, resisting tissues fibrosis, controlling viral infection, controlling infection of pathogenic bacteria, controlling neurodegenerative diseases, reducing the risk caused by the occurrence of myocardial infarction or cerebral apoplexy or cardiovascular diseases, alleviating myocardial ischemia, alleviating cerebral ischemia, protecting brain cells and brain cells, reducing blood lipid and controlling cardiovascular and cerebrovascular diseases.
In the group of gastric juice susceptibility-guided therapy, the eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.